XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

48-mm for Long Lesions

Request a Rep

Clinical Evidence in Long Lesions with 48 mm XIENCE™ Stent

The XIENCE Skypoint™ 48 mm Stent is designed so that interventional cardiologists (ICs) can use only one stent in long coronary lesions. Diffuse coronary disease—with long lesions—can otherwise be challenging when employing multiple stents.²

XIENCE Skypoint 48-mm Stent for long lesions can preclude the need for multiple overlapping stents.

Advantages in Using a Single Long Stent²

There are several advantages in using a single long stent vs several shorter stents in percutaneous coronary intervention (PCI):

Reduces procedure time, making PCIs faster and more efficient
Reduces radiation and fluoroscopy time
Reduces use of contrast

Use of a single longer stent, vs 2 shorter stents, also reduces overlap. In fact, stent overlap has been reported in as many as 30% of patients undergoing PCI. Overlapping stents may also result in:

Increased risk of stent fracture³
Higher rates of target lesion revascularization (TLR)²

XIENCE Skypoint™ Stent also offers a new 4.0 x 48mm stent size to help treat larger vessels where there may be diffuse disease.

XIENCE™ 48 mm Stent Safety Outcomes^†

Long XIENCE™ Stents continue the tradition of excellent XIENCE™ safety outcomes. XIENCE™ 48 mm Stents demonstrate impressive outcomes in long lesions:

100% device success (mean stented length 58 mm)⁴
0.1% definite/probable stent thrombosis (ST) 24 hours post-procedure (mean stented length 39.3 mm)⁵

Data from XIENCE Prime™ Stent & XIENCE Xpedition™ Stent

In long lesions, XIENCE 48-mm stents achieved 100% device success.

In long lesions, 48-mm stents achieved 0.1% acute definite or probable stent thrombosis.

Long-Term Outcomes in Long, Complex Lesions⁴

When using XIENCE™ 48 mm Stents in long, complex lesions, there were low rates of myocardial infarction (MI), TLR, and major adverse cardiac events (MACE) 1 year after the index procedure. In this analysis the mean stented length was 58 mm.

When treating long, complex lesions, XIENCE Stent 1-year data showed 0.8% MI, 0.8% TLR, and 3.3% MACE rates.

Consistent Outcomes with Moderate / Long Length Stents⁶

Additional data supported the safety of XIENCE™ Stent in long lesions, with findings displaying consistent performance between moderate length lesions and long lesions.

	Moderate Length Lesions (> 24 mm to < 35 mm) 482 patients	Long Length Lesions (> 35 mm) 323 patients	p value
TLF at 1 Year	10%	8.9%	p = 0.63
Mean Lesion Length	28.1 mm	47.1 mm	p < 0.0001

Lower Revascularization in Chronic Total Occlusions (CTO)⁷

Among the 3-year outcomes of the PRISON-IV trial, the XIENCE™ Stent resulted in significantly lower TLR rates of 4.2% compared to 11.5% with biodegradable polymer sirolimus-eluting stents (BP-SES). The population encompassed patients with complex CTOs.

Total stented length with XIENCE™ Stent: 52.3 mm
Total stented length with BP-SES: 52.4 mm

When treating CTOs in long lesions, XIENCE Stent has significantly lower target lesion revascularization rate of 4.2% vs 11.5% with BP-SES.

Excellent Long-Term Outcomes at 5 Years⁸

The 5-year data from the IVUS-XPL study reveal excellent XIENCE™ Stent outcomes in long lesion treatment guided by intravascular ultrasound (IVUS). Study results show low event rates with long lesions treated with long stents.

Mean lesion length: 35.1 mm
Total stented length: 39.4 mm

Note the low rates of both definite or probable ST (0.3%) and MACE (5.6%).

XIENCE Stent has much lower platelet adhesion compared to Synergy, Orsiro, Ultimaster, Onyx, and BioFreedom drug-eluting stents

Manuals & Technical Resources

Cardiovascular Products

Customer Service

^† XIENCE™ Stent safety outcomes include data on XIENCE Prime™ Stent & XIENCE Xpedition™ Stent.

References

Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
Jurado-Román A, et al. Cardiovasc Revasc Med. 2019;20(8):681-686.
Chinikar M, et al. Current Cardiol Rev. 2014;10:349-354.
Tan CK, et al. Herz. 2019;44:419-424
Hong SFJ, et al. J Am Coll Cardiol Intv. 2016;9:1438-1446.
Bouras G, et al. Catheter Cardiovasc Interv. 2017;89(6):984-991.
Zivelonghi C, et al. JACC Cardiovasc Interv. 2019;12(17):1747-1749. Teeuwen K, et al. JACC Cardiovasc Interv. 2017;10(2):133-143.
Hong SJ, et al. JACC Cardiovasc Interv. 2020;13(1):62-71.

MAT-2107575 v1.0

CARDIOVASCULAR

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹